NCT04748185View on ClinicalTrials.gov

Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies

CompletedOBSERVATIONAL
Enrollment

358

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

July 13, 2022

Study Completion Date

July 13, 2022

Conditions
Monoclonal B-Cell LymphocytosisChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaB-cell Non Hodgkin LymphomaHodgkin Lymphoma
Trial Locations (1)

55902

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER